<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3122">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04821570</url>
  </required_header>
  <id_info>
    <org_study_id>IIT-2021-CANINE</org_study_id>
    <nct_id>NCT04821570</nct_id>
  </id_info>
  <brief_title>To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Treatment</brief_title>
  <acronym>CANINE</acronym>
  <official_title>Cancer Therapy and Immunogenicity of COVID Vaccine (CANINE Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kansas Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kansas Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a trial of prospective collection of serial blood samples after administration of&#xD;
      COVID-19 vaccine in patients with cancer who are receiving active cancer treatment, planned&#xD;
      to start therapy with 14 days of consent, or have had stem cell transplant. Cancer treatments&#xD;
      and administration of vaccine are not controlled by the study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">March 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Geometric mean titer (GMT) with corresponding 95%confidence interval (CI) at each time point of the entire population and individually of all cohorts</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Pfizer: Baseline, Day 21, Day 51, Day 111, Day 201.</time_frame>
    <description>Elecsys Anti severe acute respiratory syndrome (SARS) coronavirus 2 (CoV 2) S quantitative assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean titer (GMT) with corresponding 95% CI at each time point of the entire population and individually of all cohorts</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Moderna: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 S quantitative assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean titer (GMT) with corresponding 95% CI at each time point of the entire population and individually of all cohorts</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Johnson &amp; Johnson: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 S quantitative assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean fold rise (GMFR) with corresponding 95% CI at each post-baseline timepoint over preinjection baseline</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Moderna: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 S quantitative assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean fold rise (GMFR) with corresponding 95% CI at each post-baseline timepoint over preinjection baseline</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Pfizer baseline, Day 21, Day 51, Day 111, Day 201</time_frame>
    <description>Elecsys Anti SARS CoV 2 S quantitative assay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean fold rise (GMFR) with corresponding 95% CI at each post-baseline timepoint over preinjection baseline</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Johnson &amp; Johnson: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 S quantitative assay</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric median, minimum and maximum assay titer values for each cohort</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Moderna: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 S quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric median, minimum and maximum assay titer values for each cohort</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Pfizer: Baseline, Day 21, Day 51, Day 111, Day 201</time_frame>
    <description>Elecsys Anti SARS CoV 2 S quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric median, minimum and maximum assay titer values for each cohort</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Johnson &amp; Johnson: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 S quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with fold-rise ≥ 2 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Moderna: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with fold-rise ≥ 2 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Moderna: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with fold-rise ≥ 3 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Moderna: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with fold-rise ≥ 3 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Moderna: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with fold-rise ≥ 4 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Moderna: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with fold-rise ≥ 4 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Moderna: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with fold-rise ≥ 2 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Pfizer: Baseline, Day 21, Day 51, Day 111, Day 201</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with fold-rise ≥ 2 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Pfizer: Baseline, Day 21, Day 51, Day 111, Day 201</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with fold-rise ≥ 3 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Pfizer: Baseline, Day 21, Day 51, Day 111, Day 201</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with fold-rise ≥ 3 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Pfizer: Baseline, Day 21, Day 51, Day 111, Day 201</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with fold-rise ≥ 4 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Pfizer: Baseline, Day 21, Day 51, Day 111, Day 201</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with fold-rise ≥ 4 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Pfizer: Baseline, Day 21, Day 51, Day 111, Day 201</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with fold-rise ≥ 2 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Johnson &amp; Johnson: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with fold-rise ≥ 2 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Johnson &amp; Johnson: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with fold-rise ≥ 3 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Johnson &amp; Johnson: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with fold-rise ≥ 3 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Johnson &amp; Johnson: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of subjects with fold-rise ≥ 4 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Johnson &amp; Johnson: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with fold-rise ≥ 4 from baseline at each post injection time points with 95% CIs</measure>
    <time_frame>Participants will have scheduled blood sampling (for immunogenicity assessment) at: For Johnson &amp; Johnson: Baseline, Day 29, Day 57, Day 119, Day 209</time_frame>
    <description>Elecsys Anti SARS CoV 2 quantitative assay</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <arm_group>
    <arm_group_label>Chemotherapy (IV and oral)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Immunotherapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy + Immunotherapy</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclin- dependent kinase (CDK) 4/6 inhibitors</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Stem Cell Transplant recipients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 Vaccine</intervention_name>
    <description>Per recommended dosing schedule</description>
    <arm_group_label>Chemotherapy (IV and oral)</arm_group_label>
    <arm_group_label>Chemotherapy + Immunotherapy</arm_group_label>
    <arm_group_label>Cyclin- dependent kinase (CDK) 4/6 inhibitors</arm_group_label>
    <arm_group_label>Immunotherapy</arm_group_label>
    <arm_group_label>Stem Cell Transplant recipients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants undergoing treatment for breast cancer, lung cancer and melanoma with&#xD;
        chemotherapy, immunotherapy and/or oral anticancer agents, or have undergone stem cell&#xD;
        transplantation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Ability of participant OR Legally Authorized Representative (LAR) to understand this&#xD;
             study, and participant or LAR willingness to sign a written informed consent&#xD;
&#xD;
          -  Males and females age ≥ 18 years&#xD;
&#xD;
          -  Patients with breast cancer, lung cancer, malignant melanoma or who have undergone&#xD;
             stem cell transplant or chimeric antigen receptor (CAR) T cell therapy for a&#xD;
             hematologic malignancy.&#xD;
&#xD;
        Other cancer types including hematologic malignancies may be allowed if they are receiving&#xD;
        treatments outlined in section 4.1.4&#xD;
&#xD;
          -  Solid Tumor patients and those with hematologic malignancies: Currently receiving&#xD;
             active anti-cancer therapy, or planned to start within 14 days, with intravenous&#xD;
             cytotoxic chemotherapy (oral or intravenous), intravenous chemoimmunotherapy&#xD;
             combination, immunotherapy alone, an oral CDK 4/6 inhibitor. (This does not apply to&#xD;
             recipients of stem cell transplant and CAR T therapy)&#xD;
&#xD;
          -  Therapy may be neo/adjuvant or for metastatic disease&#xD;
&#xD;
          -  Eastern Cooperation Oncology Group (ECOG) Performance status (PS) of 0-2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        * Life expectancy of &lt; 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Qamar Khan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kansas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>KUCC Navigation</last_name>
    <phone>9135883671</phone>
    <email>kucc_navigation@kumc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Kansas Cancer Center, Westwood Campus</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>KUCC Navigation</last_name>
      <phone>913-588-3671</phone>
      <email>kucc_navigation@kumc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2021</study_first_posted>
  <last_update_submitted>March 26, 2021</last_update_submitted>
  <last_update_submitted_qc>March 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

